Paper34355232
Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.
Schoretsanitis G and 3 others. Schizophr Bull, 2022. Cited by 38 papers, by iCite.
Cite this record
ConductScience Library. Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data. Papers, record 34355232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34355232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antipsychotic Agents | Major topic |
| Medication Adherence | Major topic |
| Recurrence | Major topic |
| Schizophrenia | Major topic |
| Administration, Oral | |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Proportional Hazards Models | |
| Drug Monitoring |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 34964477 | Confounding of Antipsychotic Discontinuation Studies by Withdrawal-Related Relapse. | https://conductscience.org/library/papers/34964477 |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30540353 | Factors Associated With Successful Medication Discontinuation After a Randomized Clinical Trial of Relapse Prevention in First-Episode Psychosis: A 10-Year Follow-up. | JAMA Psychiatry | 2019 | https://conductscience.org/library/papers/30540353 | PubMed |
| 2 | 29146020 | Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review. | Schizophr Res | 2018 | https://conductscience.org/library/papers/29146020 | PubMed |
| 3 | 21920710 | Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study. | Eur Psychiatry | 2013 | https://conductscience.org/library/papers/21920710 | PubMed |
| 4 | 32828165 | Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis. | Lancet Psychiatry | 2020 | https://conductscience.org/library/papers/32828165 | PubMed |
| 5 | 32220153 | Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study. | J Clin Psychiatry | 2020 | https://conductscience.org/library/papers/32220153 | PubMed |
| 6 | 28277310 | Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis. | Schizophr Res | 2017 | https://conductscience.org/library/papers/28277310 | PubMed |
| 7 | 23558429 | Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. | Am J Psychiatry | 2013 | https://conductscience.org/library/papers/23558429 | PubMed |
| 8 | 23612934 | A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong. | Aust N Z J Psychiatry | 2013 | https://conductscience.org/library/papers/23612934 | PubMed |
| 9 | 26939910 | Altering the course of schizophrenia: progress and perspectives. | Nat Rev Drug Discov | 2016 | https://conductscience.org/library/papers/26939910 | PubMed |
| 10 | 31866076 | Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy. | Schizophr Res | 2020 | https://conductscience.org/library/papers/31866076 | PubMed |
| 11 | 25066792 | Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. | Psychol Med | 2014 | https://conductscience.org/library/papers/25066792 | PubMed |
| 12 | 29856543 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? | World Psychiatry | 2018 | https://conductscience.org/library/papers/29856543 | PubMed |
| 13 | 6275811 | Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. | Arch Gen Psychiatry | 1982 | https://conductscience.org/library/papers/6275811 | PubMed |
| 14 | 23756298 | The evidence for illness progression after relapse in schizophrenia. | Schizophr Res | 2013 | https://conductscience.org/library/papers/23756298 | PubMed |
| 15 | 31059621 | Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. | World Psychiatry | 2019 | https://conductscience.org/library/papers/31059621 | PubMed |
| 16 | 25562685 | Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. | J Clin Psychiatry | 2015 | https://conductscience.org/library/papers/25562685 | PubMed |
| 17 | 26189570 | Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. | J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/26189570 | PubMed |
| 18 | 31922669 | 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). | World Psychiatry | 2020 | https://conductscience.org/library/papers/31922669 | PubMed |
| 19 | 12892869 | Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis. | Schizophr Res | 2003 | https://conductscience.org/library/papers/12892869 | PubMed |
| 20 | 26811679 | Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study. | Neuropsychiatr Dis Treat | 2016 | https://conductscience.org/library/papers/26811679 | PubMed |
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42847024 | Are Depot Antipsychotics Ever Self-Tapering? Exploring the Discontinuation of Long-Acting Injectable Psychosis Drugs and Those With Delayed Onset Through In Silico Modelling. | Schizophr Bull Open | 2026 | https://conductscience.org/library/papers/42847024 | PubMed |
| 41910757 | [Olanzapine long acting injectable in new application form-Hope for the absence of post-injection delirium/sedation syndromes]. | Nervenarzt | 2026 | https://conductscience.org/library/papers/41910757 | PubMed |
| 41511922 | Community management: An effective model to reduce medication discontinuation rate in patients with schizophrenia. | PLoS One | 2026 | https://conductscience.org/library/papers/41511922 | PubMed |
| 41407750 | Helping people to discontinue antipsychotics: if, when and how. | Schizophrenia (Heidelb) | 2025 | https://conductscience.org/library/papers/41407750 | PubMed |
| 41057718 | The Use of Long-Acting Injectables for People with Schizophrenia: Consensus Panel Recommendations for Overcoming Barriers and Implementing Treatment. | Neurol Ther | 2025 | https://conductscience.org/library/papers/41057718 | PubMed |
| 41019822 | Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia. | Neuropsychiatr Dis Treat | 2025 | https://conductscience.org/library/papers/41019822 | PubMed |
| 40971553 | Not So Hasty: The Effect of Tapering Speed on Relapse May Still Be Important. | Schizophr Bull | 2026 | https://conductscience.org/library/papers/40971553 | PubMed |
| 40958797 | Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices. | Front Psychiatry | 2025 | https://conductscience.org/library/papers/40958797 | PubMed |
| 40826949 | Long-acting injectable antipsychotics for patients with first-episode and early-phase schizophrenia: still not considered often enough. | CNS Spectr | 2025 | https://conductscience.org/library/papers/40826949 | PubMed |
| 39282238 | Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs. | Ther Adv Psychopharmacol | 2024 | https://conductscience.org/library/papers/39282238 | PubMed |
| 38868633 | The pharmacological treatment of schizophrenia: How far have we come? | PCN Rep | 2022 | https://conductscience.org/library/papers/38868633 | PubMed |
| 38275523 | Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug. | Brain Sci | 2024 | https://conductscience.org/library/papers/38275523 | PubMed |
| 38250810 | The effects of antipsychotic discontinuation or maintenance on the process of recovery in remitted first-episode psychosis patients - A systematic review and meta-analysis of randomized controlled trials. | Eur Psychiatry | 2024 | https://conductscience.org/library/papers/38250810 | PubMed |
| 37935711 | Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly. | Schizophrenia (Heidelb) | 2023 | https://conductscience.org/library/papers/37935711 | PubMed |
| 37797288 | Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse. | Schizophr Bull | 2024 | https://conductscience.org/library/papers/37797288 | PubMed |
| 37786804 | Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia. | Ther Adv Psychopharmacol | 2023 | https://conductscience.org/library/papers/37786804 | PubMed |
| 37719449 | Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study. | Ther Adv Psychopharmacol | 2023 | https://conductscience.org/library/papers/37719449 | PubMed |
| 36277256 | Chronic Use of Antipsychotics in Schizophrenia: Are We Asking the Right Question? | Schizophr Bull Open | 2022 | https://conductscience.org/library/papers/36277256 | PubMed |
| 35573364 | Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis. | Front Psychiatry | 2022 | https://conductscience.org/library/papers/35573364 | PubMed |
| 35543395 | Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries. | Epidemiol Psychiatr Sci | 2022 | https://conductscience.org/library/papers/35543395 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34355232
GET https://conductscience.org/api/papers/v1/34355232/references?page=2